Invivo Therapeutics Holdings Corp (NVIV) reported quarterly earnings results on Friday, May-6-2016. The company said it had a profit of $-0.20 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.06. Analysts had a consensus of $-0.26. During the same quarter in the previous year, the company posted $-0.24 EPS.
Invivo Therapeutics Holdings Corp opened for trading at $5.77 and hit $5.9 on the upside on Wednesday, eventually ending the session at $5.87, with a gain of 1.21% or 0.07 points. The heightened volatility saw the trading volume jump to 4,47,216 shares. Company has a market cap of $162 M.
In a different news, on Aug 14, 2015, C Ann Merrifield (director) purchased 2,000 shares at $12.36 per share price.
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The Company’s technologies incorporate intellectual property licensed under an exclusive around the world license from Boston Children’s Hospital (BCH) and the Massachusetts Institute of Technology (MIT) and intellectual property that has been developed internally including in collaboration with its advisors and partners. The Company intends to leverage its platform technology to develop the Neuro-Spinal Scaffold an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury (SCI). The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.